Fractyl Health, Inc. (NASDAQ:GUTS) Given Consensus Rating of “Hold” by Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $5.40.

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th.

Insider Activity at Fractyl Health

In related news, Director William Bradley acquired 68,493 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was purchased at an average cost of $0.73 per share, with a total value of $49,999.89. Following the completion of the acquisition, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This trade represents a 424.66% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ian Sheffield acquired 35,000 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, with a total value of $25,550.00. Following the completion of the acquisition, the director directly owned 35,000 shares of the company’s stock, valued at $25,550. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 148,493 shares of company stock valued at $107,600 over the last three months. 8.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. FNY Investment Advisers LLC purchased a new position in shares of Fractyl Health during the third quarter valued at approximately $31,000. Jane Street Group LLC purchased a new stake in Fractyl Health during the second quarter valued at approximately $31,000. Accredited Investors Inc. purchased a new stake in Fractyl Health during the first quarter valued at approximately $46,000. Scientech Research LLC purchased a new stake in Fractyl Health during the third quarter valued at approximately $49,000. Finally, Prelude Capital Management LLC purchased a new stake in Fractyl Health during the third quarter valued at approximately $55,000.

Fractyl Health Stock Performance

Shares of NASDAQ GUTS opened at $0.85 on Wednesday. The firm’s 50 day moving average price is $0.69 and its 200-day moving average price is $1.07. The company has a market cap of $134.85 million, a PE ratio of -0.66 and a beta of 2.34. Fractyl Health has a 52-week low of $0.38 and a 52-week high of $2.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23. On average, equities research analysts expect that Fractyl Health will post -0.6 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.